Urolithin A: The Mitophagy Activator Your Mitochondria Need (2026)

Your cells contain hundreds to thousands of mitochondria. These organelles generate the ATP (adenosine triphosphate – your cells' primary energy currency) that powers virtually every cellular function – from muscle contraction to DNA repair to neurotransmitter synthesis. When mitochondria are healthy, everything works. When they're damaged, they leak ROS (reactive oxygen species – unstable molecules that damage cells when levels are too high), trigger inflammation, and drag cellular performance down.

The body has a quality-control system for this: mitophagy – the selective removal and recycling of damaged mitochondria. But mitophagy declines with age. Damaged mitochondria accumulate. Energy production drops.

Urolithin A is the first compound clinically demonstrated to reactivate mitophagy in humans. It triggers the PINK1/Parkin pathway – the cell's primary mitochondrial quality-control mechanism – and clinical trials show measurable improvements in muscle endurance and mitochondrial biomarkers.

Here's the catch: your body doesn't make urolithin A directly. Gut bacteria produce it from ellagitannins found in pomegranates and berries – and roughly 60-70% of people lack the bacterial species to make this conversion efficiently.

This guide covers the full science: what urolithin A does, how mitophagy works, the clinical evidence, why most people need direct supplementation, and how it fits into a longevity protocol.

TL;DR

• Urolithin A is a gut-bacteria-derived metabolite that activates PINK1/Parkin mitophagy – the cell's system for removing damaged mitochondria
• Mitophagy declines with age, leading to accumulation of dysfunctional mitochondria that produce excess ROS and drive inflammaging
• Clinical trials (Andreux et al. 2019, Singh et al. 2022, Liu et al. 2022) show urolithin A supplementation improves mitochondrial biomarkers and muscle endurance in older adults
• 60-70% of people are "non-converters" – they lack the gut bacteria to produce urolithin A from dietary ellagitannins (pomegranates, walnuts, berries)
• Typical clinical dose: 500-1,000mg/day of direct urolithin A
• Urolithin A complements NAD+ precursors: NMN fuels mitochondria while urolithin A removes the damaged ones

Quick Facts: Urolithin A

• Dose: 500-1,000 mg/day
• Form: Direct synthetic urolithin A (not pomegranate extract)
• Timing: With a fat-containing meal
• Evidence: Strong (3 human RCTs showing muscle endurance and mitochondrial biomarker improvements)
• Who it's for: Anyone over 40 seeking mitochondrial quality control, especially non-converters (60-70% of people)

Mitophagy: Your Mitochondrial Quality Control System

Before understanding urolithin A, you need to understand the problem it solves.

Mitochondria aren't permanent structures. They have a lifespan of roughly 10-25 days in most tissues. Healthy cellular maintenance involves a constant cycle: new mitochondria are built (biogenesis), functioning mitochondria divide (fission) and merge (fusion), and damaged mitochondria are tagged for removal and recycling.

That removal process is mitophagy – a specialized form of autophagy (your cells' self-cleaning process – recycling damaged components into usable parts) targeting mitochondria specifically.

The PINK1/Parkin Pathway

The best-characterized mitophagy pathway involves two proteins: PINK1 (PTEN-induced kinase 1) and Parkin (an E3 ubiquitin ligase). Here's how it works:

In healthy mitochondria: PINK1 is continuously imported into the mitochondrion, where it's rapidly cleaved and degraded. PINK1 never accumulates on healthy mitochondria.

In damaged mitochondria: When the mitochondrial membrane potential drops (indicating damage), PINK1 import is blocked. PINK1 accumulates on the outer mitochondrial membrane, where it:

1. Phosphorylates ubiquitin molecules on the mitochondrial surface
2. Recruits and activates Parkin from the cytoplasm
3. Parkin adds more ubiquitin chains, amplifying the "eat me" signal
4. Ubiquitinated mitochondria are recognized by autophagy receptors (OPTN, NDP52)
5. An autophagosome engulfs the damaged mitochondrion
6. The autophagosome fuses with a lysosome, and the mitochondrion is digested and recycled

It's elegant engineering: only damaged mitochondria accumulate the PINK1 signal. Healthy ones never get tagged.

Why Mitophagy Declines With Age

Multiple mechanisms converge to impair mitophagy in aging:

PINK1 and Parkin expression decrease. Gene expression studies show age-related downregulation of both PINK1 and Parkin in multiple tissues. A 2018 study in Aging Cell (Drummond et al.) documented reduced Parkin expression in aged human skeletal muscle.

NAD+ decline impairs the upstream regulators. SIRT1 and SIRT3 – NAD+-dependent sirtuins – regulate mitophagy initiation. When NAD+ falls, sirtuin activity drops, and the mitophagy trigger becomes less sensitive.

AMPK signaling weakens. AMPK (AMP-activated protein kinase) is another key mitophagy initiator. AMPK sensitivity decreases with age, partly due to chronic nutrient excess and reduced physical activity.

Lysosomal function declines. Even when damaged mitochondria are properly tagged and engulfed, the lysosomes that digest them become less efficient with age. Lipofuscin (cellular "waste") accumulates in lysosomes, reducing their degradative capacity.

The result: damaged mitochondria pile up. They produce excess reactive oxygen species (ROS), which damage neighboring mitochondria and other cellular structures. They trigger inflammatory signaling via the NLRP3 inflammasome. They consume resources without producing adequate ATP.

This isn't a minor problem. Mitochondrial dysfunction is one of the 12 hallmarks of aging, and it interconnects with at least six others: genomic instability, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, cellular senescence, and altered intercellular communication.

What Urolithin A Does

Urolithin A (UA) is a small molecule classified as a dibenzopyranone. It activates mitophagy through several converging mechanisms:

1. PINK1/Parkin Pathway Activation

Urolithin A upregulates PINK1 expression and enhances Parkin recruitment to damaged mitochondria. In cell culture studies, UA treatment increases the proportion of mitochondria undergoing active mitophagy by 2-4 fold, depending on cell type and baseline mitophagy activity.

2. AMPK Activation

UA activates AMPK, the cellular energy sensor that promotes catabolic (breakdown and recycling) processes when energy is scarce. AMPK activation independently promotes mitophagy through ULK1 phosphorylation, which initiates autophagosome formation.

3. Mitochondrial Membrane Potential Modulation

Research suggests UA may selectively depolarize already-compromised mitochondria, accelerating their clearance without affecting healthy mitochondria. This "selective sensitization" mechanism would explain why UA improves overall mitochondrial function without reducing total mitochondrial mass.

4. Anti-inflammatory Effects via Mitochondrial Cleanup

By removing damaged mitochondria before they leak mitochondrial DNA (mtDNA) and other damage-associated molecular patterns (DAMPs) into the cytoplasm, UA reduces activation of the NLRP3 inflammasome and cGAS-STING pathway – both of which drive age-related inflammation.

A 2016 study in Nature Medicine (Ryu et al.) demonstrated that urolithin A extended lifespan in C. elegans by ~45% and improved muscle function in rodents – entirely through mitophagy activation. When mitophagy genes (PINK-1, PDR-1/Parkin) were knocked out in C. elegans, the benefits disappeared, confirming that mitophagy is the primary mechanism.

Key Takeaway: Urolithin A activates the PINK1/Parkin mitophagy pathway — the same quality control system that tags damaged mitochondria for removal. By selectively eliminating dysfunctional mitochondria while leaving healthy ones intact, urolithin A improves the overall quality of your mitochondrial population. This is cellular quality control, not just antioxidant protection.

The Human Clinical Evidence

Urolithin A has one of the strongest clinical evidence bases of any mitophagy-targeting compound.

Andreux et al., 2019 – Nature Metabolism (First-in-Human Study)

• Design: Randomized, double-blind, placebo-controlled. 60 healthy elderly sedentary adults. Single doses (250mg, 500mg, 1,000mg, 2,000mg) followed by a 28-day multiple-dose phase (250mg and 1,000mg daily).
• Key findings: UA was safe and bioavailable at all doses. The 28-day phase showed a dose-dependent improvement in mitochondrial biomarkers – downregulation of acylcarnitines (markers of incomplete fatty acid oxidation, indicating mitochondrial inefficiency) and upregulation of mitophagy gene expression in skeletal muscle biopsies.
• Why it matters: This established safety, bioavailability, and the molecular mechanism in humans.

Liu et al., 2022 – JAMA Network Open (Muscle Endurance in Older Adults)

• Design: Randomized, double-blind, placebo-controlled. 66 adults aged 65-90 with low muscle endurance. 1,000mg UA daily for 4 months.
• Key findings: Significant improvement in muscle endurance (hand grip and tibialis anterior endurance tests). Reduced plasma acylcarnitines and C-reactive protein (CRP, an inflammatory marker).
• Why it matters: This demonstrated that mitophagy activation translates to real-world muscle endurance improvements in older adults.

Singh et al., 2022 – Cell Reports Medicine (Muscle Strength and Biomarkers)

• Design: Randomized, double-blind, placebo-controlled. 88 middle-aged overweight adults. 500mg and 1,000mg UA daily for 4 months.
• Key findings: Significant improvement in muscle strength (~12%). Both doses improved six-minute walk distance. Plasma acylcarnitines decreased (improved mitochondrial efficiency). CRP decreased at both doses.
• Why it matters: Extended the evidence to middle-aged adults (not just elderly) and showed strength and cardiovascular fitness improvements alongside mitophagy markers.

Combined Evidence Pattern

Across trials: urolithin A at 500-1,000mg/day consistently:

• Activates mitophagy gene expression in human muscle tissue
• Reduces acylcarnitine biomarkers (indicating improved mitochondrial fatty acid oxidation)
• Reduces CRP (systemic inflammation marker)
• Improves muscle endurance metrics
• Shows no significant adverse effects

The Gut Bacteria Problem

Urolithin A doesn't exist in food. It's produced by gut bacteria from ellagitannins – polyphenols found in pomegranates, walnuts, strawberries, raspberries, and certain other fruits and nuts.

The conversion pathway:

1. You eat ellagitannin-rich foods
2. Stomach acid and intestinal enzymes release ellagic acid from ellagitannins
3. Specific gut bacteria (primarily Gordonibacter urolithinfaciens and Ellagibacter isourolithinifaciens) convert ellagic acid through several intermediates to urolithin A
4. Urolithin A is absorbed in the colon and enters systemic circulation

The problem: this bacterial conversion is highly variable across individuals.

A 2014 study in the Journal of Agricultural and Food Chemistry (Tomas-Barberan et al.) categorized people into three "metabotypes" based on their urolithin production capacity after pomegranate consumption:

• Metabotype A (~30-40%): Produce urolithin A efficiently. These individuals have the right bacterial species in sufficient abundance.
• Metabotype B (~50-60%): Produce urolithin B and isourolithin A – different metabolites with weaker or different biological activity. These individuals have some conversion capacity but produce the "wrong" end products.
• Metabotype 0 (~10-15%): Produce no detectable urolithins. They completely lack the relevant bacterial species.

Combined, 60-70% of people cannot efficiently produce urolithin A from dietary sources – regardless of how many pomegranates they eat. This biological reality is why direct urolithin A supplementation exists.

Age makes this worse. The bacterial species responsible for urolithin A production tend to decline with age, meaning older adults – who need mitophagy support most – are least likely to produce it from food.

Key Takeaway: The Amazentis ATLAS trial (n=66, 4 months) showed that 500-1000mg/day of Mitopure (urolithin A) improved muscle endurance and mitochondrial biomarkers in older adults. Additional trials show improved mitochondrial function as measured by ATP production. This is legitimate human RCT data — stronger than most longevity supplement evidence.

Direct Supplementation: Bypassing the Gut Bottleneck

Direct urolithin A supplementation avoids the microbiome conversion problem entirely. The clinical trials cited above all used synthetic urolithin A (the compound itself, not pomegranate extract), confirming that direct supplementation is bioavailable and effective.

Dosing

• Clinical trial range: 250mg to 1,000mg daily
• Effective dose for functional outcomes: 500-1,000mg daily (Liu et al. 2022)
• Typical supplement dose: 500mg daily

Timing

No specific timing data exists for urolithin A. It's fat-soluble, so taking it with a meal containing fat may improve absorption. Half-life studies show peak plasma levels at approximately 6 hours post-ingestion, with urolithin A metabolites detectable for 24-48 hours – suggesting once-daily dosing is sufficient.

Safety Profile

Safety Note: Urolithin A has GRAS status and a clean safety profile in published trials. However, long-term data beyond 4 months is limited. Pregnant and breastfeeding women should avoid supplementation due to insufficient safety data.

Across all published human trials:

• No serious adverse events
• Minor GI symptoms (nausea, mild discomfort) reported at rates similar to placebo
• No drug interactions identified to date
• The compound has received GRAS (Generally Recognized as Safe) status from the FDA

How mitophagy activators compare:

Urolithin A vs. Other Mitophagy Strategies

How does urolithin A compare to other approaches that activate mitophagy?

Exercise

Exercise is the most potent natural mitophagy activator. Endurance exercise activates AMPK, upregulates PINK1/Parkin, and triggers mitochondrial biogenesis simultaneously. A 2019 study in Science Translational Medicine showed that exercise-induced mitophagy was essential for exercise's anti-aging effects in muscle.

Urolithin A doesn't replace exercise. But for individuals who are sedentary, mobility-limited, or aging – precisely the populations where mitophagy is most impaired – it provides pharmacological mitophagy activation that partially mimics exercise's mitochondrial quality-control benefits.

NAD+ Precursors (NMN/NR)

NAD+ precursors and urolithin A target different aspects of mitochondrial health:

• NMN fuels existing mitochondria by restoring NAD+ levels, supporting the electron transport chain and sirtuin activity
• Urolithin A removes damaged mitochondria through mitophagy, improving the average quality of the remaining pool

These are complementary, not redundant. Think of it this way: NMN provides better fuel for the engine. Urolithin A removes the engines that are broken. Together, you get more efficient mitochondria producing more ATP with less collateral damage.

Spermidine

Spermidine activates autophagy (including mitophagy) through a different mechanism – inhibition of acetyltransferase EP300, leading to protein deacetylation and autophagy induction. It's a broader autophagy inducer, while urolithin A is more specifically targeted to mitochondrial autophagy. They can be used in combination.

Rapamycin

Rapamycin inhibits mTOR, which indirectly promotes autophagy and mitophagy. However, rapamycin is a prescription drug with immunosuppressive effects and requires medical supervision. Urolithin A achieves mitophagy activation through a different pathway without the immunosuppressive risk.

Emerging Research Directions

Brain Mitophagy and Neurodegeneration

One of the most exciting frontiers for urolithin A research is its potential role in neurodegenerative diseases. Mitochondrial dysfunction is a hallmark of both Alzheimer's and Parkinson's disease. In Alzheimer's, amyloid-beta plaques impair mitochondrial function. In Parkinson's, mutations in PINK1 and Parkin genes directly cause mitophagy failure.

Preclinical studies have shown that urolithin A can cross the blood-brain barrier and activate mitophagy in neuronal cells. Fang et al. (2019, Nature Neuroscience) demonstrated that urolithin A treatment improved memory in Alzheimer's disease mouse models by clearing damaged mitochondria from neurons. The compound reduced amyloid-beta pathology and tau phosphorylation – both core drivers of Alzheimer's progression.

Human clinical trials for urolithin A in mild cognitive impairment are in the planning stages. If the neurological benefits translate from animals to humans, urolithin A could become relevant not just for muscle health but for brain aging.

Cardiac Mitophagy

The heart is the most mitochondria-dense organ in the body – mitochondria make up approximately 30% of cardiomyocyte volume. Cardiac mitophagy decline is a significant contributor to age-related heart failure, particularly diastolic dysfunction.

Animal studies show that urolithin A supplementation improves cardiac function in aged mice by clearing damaged mitochondria and reducing cardiac inflammation. Whether this translates to improved cardiac outcomes in humans is under active investigation.

Combination Studies

Researchers are beginning to study urolithin A in combination with other longevity compounds. The mechanistic rationale for combining urolithin A with NAD+ precursors (clearing damaged mitochondria while fueling healthy ones) or with spermidine (mitophagy plus general autophagy) has prompted formal investigation. Early results from preclinical combination studies suggest additive or synergistic effects, but human data is needed.

Key Takeaway: Only 40% of people can naturally convert ellagic acid (from pomegranates) into urolithin A — it depends on specific gut bacteria that many people lack. Direct supplementation with synthetic urolithin A bypasses this bottleneck entirely, providing reliable dosing regardless of your microbiome composition. The trade-off is cost: Mitopure runs $95-125/month.

How Urolithin A Fits Into a Longevity Protocol

Urolithin A addresses one of the 12 hallmarks of aging – mitochondrial dysfunction – through a specific, validated mechanism. In a structured longevity supplement protocol:

Foundation layer (NAD+ support): NMN at 600mg/day to restore the coenzyme that mitochondria need for energy production and sirtuin function.

Quality control layer (mitochondrial cleanup): Urolithin A at 500mg/day to remove damaged mitochondria via PINK1/Parkin mitophagy, improving the average quality of the mitochondrial pool.

Biogenesis layer: PQQ at 20mg/day to stimulate production of new mitochondria through PGC-1alpha activation – replacing the damaged ones that urolithin A removes.

This three-layer approach – fuel, cleanup, and replacement – addresses mitochondrial health from all angles.

The Bottom Line

Urolithin A is the first clinically validated compound to activate mitophagy in humans. It triggers the PINK1/Parkin pathway – the cell's primary system for removing damaged mitochondria – and multiple randomized controlled trials confirm it improves muscle endurance, mitochondrial biomarkers, and inflammatory markers in older and middle-aged adults.

The microbiome bottleneck is real: most people can't produce adequate urolithin A from food alone. Direct supplementation at 500-1,000mg/day bypasses this limitation with a strong safety profile.

In the broader context of longevity supplementation, urolithin A fills a specific gap. NAD+ precursors like NMN keep mitochondria fueled. Urolithin A clears out the ones that are broken. Both matter. For evidence scores on urolithin A, NMN, and every other longevity compound, see the Compound Index.

References:

1. Ryu D, et al. (2016). Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine, 22(8), 879-888.
2. Andreux PA, et al. (2019). The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism, 1, 595-603.
3. Liu S, et al. (2022). Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA Network Open, 5(1), e2144279.
4. Singh A, et al. (2022). Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine, 3(5), 100633.
5. Drummond MJ, et al. (2018). Downregulation of E3 ubiquitin ligases and mitophagy-related genes in skeletal muscle of physically inactive, frail older women. Aging Cell, 17(4), e12775.
6. Tomas-Barberan FA, et al. (2014). Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials. Journal of Agricultural and Food Chemistry, 62(28), 6535-6538.
7. Yi L, et al. (2023). The efficacy and safety of NMN supplementation in healthy middle-aged adults. GeroScience, 45(1), 29-43.

Frequently Asked Questions

Related Reading

• The Mitochondrial Theory of Aging: Why Your Cellular Power Plants Matter
• CoQ10 Ubiquinol: The Mitochondrial Fuel Your Body Stops Making After 40
• PQQ: The Compound That Builds New Mitochondria
• Autophagy Explained: Cellular Recycling, Fasting, Exercise, and Aging
• Methylene Blue: From Lab Stain to Longevity Compound
• Gut Microbiome and Longevity: What Your Bacteria Have to Do With Aging

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.